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Highly Selective Tau-SPECT 
Imaging Probes for Detection 
of Neurofibrillary Tangles in 
Alzheimer’s Disease
Masahiro Ono1, Hiroyuki Watanabe1, Ayane Kitada1, Kenji Matsumura1, Masafumi Ihara2 & 
Hideo Saji1
Neurofibrillary tangles composed of aggregates of hyperphosphorylated tau proteins are one of the 
neuropathological hallmarks of Alzheimer’s disease (AD) in addition to the deposition of β-amyloid 
plaques. Since the deposition of tau aggregates is closely associated with the severity of AD, the  
in vivo detection of tau aggregates may be useful as a biomarker for the diagnosis and progression of 
AD. In this study, we designed and synthesized a new series of radioiodinated benzoimidazopyridine 
(BIP) derivatives, and evaluated their utility as single photon emission computed tomography (SPECT) 
imaging agents targeting tau aggregates in AD brains. Five radioiodinated BIP derivatives were 
successfully prepared in high radiochemical yields and purities. In in vitro autoradiographic studies 
using postmortem AD brains, all BIP derivatives displayed high accumulation of radioactivity in the 
brain sections with abundant neurofibrillary tangles, while no marked radioactivity accumulation was 
observed in the brain sections with only β-amyloid aggregates, indicating that the BIP derivatives 
exhibited selective binding to tau aggregates. Biodistribution studies in normal mice showed high 
brain uptake at 2 min postinjection (3.5–4.7% ID/g) and rapid clearance at 60 min postinjection (0.04–
0.23% ID/g), which is highly desirable for tau imaging agents. The results of the present study suggest 
that [123I]BIP derivatives may be useful SPECT agents for the in vivo imaging of tau aggregates in AD.
Alzheimer’s disease (AD), characterized by declines in memory and recognition, constitutes a representative neu-
rodegenerative disorder. As the population ages throughout the world, a rapid increase in the number of patients 
with AD is a concern. However, the early and definitive diagnosis of AD is difficult solely based on an interview or 
a conventional diagnostic imaging technique, including measurements of a glucose metabolism or cerebral blood 
flow with nuclear medical imaging techniques, such as positron emission tomography (PET) or single photon 
emission computed tomography (SPECT)1. Therefore, the establishment of a diagnostic imaging technique that 
can diagnose AD precisely is strongly desired. The pathological changes in the AD brain include senile plaques 
and neurofibrillary tangles, which are formed by aggregates of β -amyloid (Aβ) peptides and hyperphosphorylated 
tau proteins, respectively2. Therefore, these pathological changes in the brains represent important targets for the 
diagnosis and therapy of AD3,4. It is well known that the nuclear medical imaging methods including PET and 
SPECT with imaging probes labeled with radionuclides can noninvasively detect in vivo biomarkers from the out-
side of the body by utilizing the high permeability of radioactive rays emitted from imaging probes. It is therefore 
expected that PET and SPECT will become applicable for the in vivo imaging of Aβ plaques and neurofibrillary 
tangles. Accordingly, a number of PET and SPECT imaging probes have been actively developed. On the basis of 
the amyloid cascade hypothesis that the deposition of Aβ plaques is the causative agent of AD5, the development 
of Aβ imaging probes that can detect Aβ plaques in vivo has been extensively carried out6–8. However, many 
clinical studies with these Aβ imaging probes revealed that there were a number of false-positive subjects who 
did not develop AD even though Aβ imaging displayed the existence of numerous Aβ plaques in their brains9–11. 
Therefore, it has been recognized that the highly precise diagnosis of AD only by Aβ imaging may be difficult.
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In contrast, it has been reported that tau aggregates develop similarly to Aβ before the development of AD, and 
there is a close correlation between tau accumulation and clinical manifestations12,13. Therefore, it has been gener-
ally accepted that tau imaging may be effective for not only the early detection of AD but also the judgment of its 
progression13–15. Currently, the development of tau imaging probes for PET is actively progressing. Among them, 
[18F]THK-511716,17, [18F]THK-535118, [18F]T80719,20, and [11C]PBB321,22 are the tau-PET imaging probes showing 
the most promise in clinical studies. Although the number of PET facilities is limited in the world, SPECT is more 
convenient than PET with regards to the number of facilities and its use of radionuclides with a longer half-life 
than PET. In order to diagnose many more AD patients including preclinical AD patients, the development of a 
tau-SPECT imaging method is important in addition to the tau-PET imaging method. However, there has been 
no report on a useful tau imaging probe with radionuclides for SPECT. We have developed tau imaging probes for 
SPECT, and have reported such probes in our recent papers23–26.
In order to image tau aggregates in vivo, requirements for tau imaging probes primarily include selective 
binding affinity for tau aggregates and high uptake into and rapid clearance from the brain at an early time 
postinjection13,15. Through our recent structure-activity relationship studies of heterocyclic phenylethenyl and 
pyridinylethenyl derivatives for the development of tau imaging probes for SPECT26, we found that one of the 
phenylethenyl benzimidazole derivatives (SBI-2, Fig. 1A) may be a promising tau imaging probe. Although this 
compound served as a tau imaging probe with regard to relatively selective binding to tau aggregates against Aβ 
aggregates and favorable pharmacokinetics in the brain, it did not show sufficient binding affinity to tau aggre-
gates to obtain clear images26. In addition, we observed photoisomerization of the ethenyl group in the molecule 
of SBI-2. To prevent the photoisomerization, in this study, we newly designed a phenylbenzimidazopyridine 
(BIP-Ph), which is formed by cyclization of SBI-2 (Fig. 1A). Moreover, we designed BIP-H which is produced by 
removing the phenyl group of BIP-Ph, and BIP-Me, BIP-OMe, and BIP-NMe2, which are produced by the intro-
duction of a methyl group, methoxy group, and dimethyamino group into BIP-H, respectively (Fig. 1A). After 
the synthesis of five novel BIP derivatives, we evaluated their utility as tau imaging probes for SPECT from the 
viewpoint of the selective binding affinity and uptake into and clearance from the brain. This is the first report on 
the development of tau-SPECT imaging probes based on the radioiodinated BIP scaffold.
Results and Discussion
Chemistry. We carried out the synthesis of BIP derivatives according to Fig. 1B. The starting materials (1 and 
5) for BIP-Ph27 and BIP-NMe228 were synthesized according to the method reported previously. The other starting 
2-bromopyridine derivatives used were commercially available products. The BIP scaffold was prepared by the 
reaction of various 2-bromopyridine derivatives with 2,5-dibromoaniline in the presence of 1,10-phenanthroline 
and cesium carbonate according to a method reported previously29 to yield target bromo compounds (6, 7, 8, 9, 
Figure 1. (A) Flow of the development of tau-SPECT imaging probes based on the BIP scaffold. (B) Synthetic 
route of BIP derivatives. (C) Radioiodination reaction of BIP derivatives.
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and 10). After the reaction for the formation of the BIP scaffold, the tributyltin derivatives (11, 12, 13, 14, and 15) 
were prepared from the corresponding bromo compounds using a conventional bromo to tributyltin exchange 
reaction catalyzed by Pd(0). The tributyltin derivatives were reacted with I2 in chloroform at room temperature 
to yield the iodo compounds (16, 17, 18, 19, and 20). The tributyltin derivatives were also used as a precursor 
for labeling with 125I. In the present study, we used 125I as radioiodine instead of 123I because of its availability 
and longer half-life. Radioiodination of BIP derivatives was performed by the iododestannyaltion reaction from 
the corresponding tributyltin derivatives using hydrogen peroxide as the oxidant (Fig. 1C). Then, we obtained 
radioiodinated BIP derivatives in 30–65% radiochemical yields and over 99% radiochemical purities after HPLC 
purification.
In vitro autoradiography using AD brain sections. In recent papers regarding the development 
of tau imaging probes, several methods to evaluate the selective binding affinity for tau aggregates have been 
reported17,19,21. Among them, we selected an in vitro autoradiographic (ARG) study using brain sections from AD 
patients, because an in vitro ARG study enables more direct evaluation than an in vitro binding assay using aggre-
gates of recombinant tau proteins. When we performed immunohistochemical staining of two kinds of AD brain 
sections (frontal and temporal lobes) with anti-Aβ antibody and anti-phosphorylated tau antibody, we could 
observe the extensive accumulation of Aβ plaques in the gray matter of the frontal lobe, but not tau aggregates 
(Figure S1A and B). In contrast, the gray matter of the temporal lobe showed marked accumulation of both Aβ 
plaques and tau aggregates in a different pattern of immunohistochemical staining (Figure S1C and D). Therefore, 
in the case that we use these two kinds of AD brain sections, ideal tau imaging probes should specifically accu-
mulate only in the temporal lobe positive for both tau and Aβ and not accumulate in the frontal lobe negative for 
tau. Also, in vitro autoradiography of each probe should correspond to the immunohistochemical staining of tau. 
On the basis of these criteria, we carried out in vitro autoradiography from the perspective of these evaluations.
Figure 2 shows the results of the in vitro autoradiography of [125I]BIP derivatives and [125I]IMPY. When we 
performed optimal adjustment of the autoradiograms for each probe, all BIP derivatives showed a similar pattern 
on in vitro autoradiography, and the marked radioactivity accumulation was specifically observed in the gray 
matter of the temporal lobe. In contrast, no marked radioactivity accumulation was found in the gray matter 
of the frontal lobe, which does not contain a tau pathology. As we mentioned above, the results of immunohis-
tochemical staining suggested that there are both Aβ plaques and neurofibrillary tangles in the gray matter of 
the temporal lobe, while only Aβ plaques mainly deposit in the gray matter of the frontal lobe. This pattern was 
completely different from that of [125I]IMPY, which is well known as a SPECT imaging probe for Aβ plaques30,31. 
[125I]IMPY showed marked binding to Aβ plaques in the gray matter of both the frontal and temporal lobes. 
Figure S2 shows comparative enlarged autoradiograms of [125I]IMPY and [125I]BIP-NMe2. The radioactivity of 
the autoradiogram of [125I]IMPY was seen as numerous spots reflecting the binding to Aβ plaques, while that of 
Figure 2. Comparison of in vitro autoradiograms with 125I-labeled BIP derivatives in AD brain sections 
from the frontal and temporal lobes. In vitro autoradiography with [125I]IMPY was also performed.
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[125I]BIP-NMe2 was observed as the laminar accumulation characteristic of neurofibrillary tangles. These results 
strongly suggest that all BIP derivatives may bind to tau aggregates selectively. Figure 3 shows a representative 
enlarged image of an in vitro ARG study using BIP-NMe2 together with that of immunohistochemical staining 
with anti-phosphorylated tau antibody. BIP-NMe2 displayed laminar radioactivity accumulation along the gray 
matter characteristic of tau accumulation, suggesting that BIP derivatives could clearly detect the tau pathology. 
Figure 3. Magnified image of an in vitro autoradiogram with [125I]BIP-NMe2 (A) and immunohistochemical 
staining of the adjacent brain section with anti-phosphorylated tau antibody (B).
Figure 4. In vitro autoradiograms of [125I]BIP-NMe2 on AD brain sections with excess BIP-NMe2 of 10 μ M (A) 
and 1 μ M (B) or without BIP-NMe2 (C).
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Furthermore, to determine whether the radioactivity accumulation of [125I]BIP-NMe2 in the gray matter of the 
temporal lobe is specific to tau aggregates, we carried out in vitro autoradiographic studies in the presence of 
excess nonradioactive BIP-NMe2 at 1 and 10 μ M (Fig. 4). As a result, the high radioactivity accumulation of [125I]
BIP-NMe2 in the brain section was markedly reduced by adding excess nonradioactive BIP-NMe2, indicating that 
[125I]BIP-NMe2 can specifically bind to tau aggregates in the brain (Fig. 4).
Quantitative analysis of autoradiography (ARG). Next, we conducted quantitative analyses of in vitro 
autoradiographic studies as described above. The regions of interest (ROIs) were set in the gray matter of the 
frontal lobe, white matter of the frontal lobe, gray matter of the temporal lobe, and white matter of the temporal 
lobe, respectively, in the ARG images (n = 3–7), and the radioactivity accumulation (cpm/mm2) in each region 
was determined for each probe (Fig. 5). As a result, all BIP derivatives showed higher radioactivity accumulation 
in the gray matter of the temporal lobe, in which abundant tau aggregates exist, than any other regions. This 
tendency was marked for BIP-Ph, BIP-Me, BIP-OMe, and BIP-NMe2 other than BIP-H. When we performed 
statistical analyses to compare the radioactivity accumulation in the gray matter between the frontal and temporal 
lobes, BIP-Ph, BIP-Me, BIP-OMe, and BIP-NMe2 showed significantly higher radioactivity levels than BIP-H. 
This also suggests that the substituted group in the BIP scaffold may play an important role in the selective bind-
ing affinity to tau aggregates. To further evaluate the selective binding between tau and Aβ , we compared the 
radioactivity accumulation observed in the gray matter of the frontal lobe with only Aβ aggregates with that 
observed in the gray matter of the temporal lobe with both Aβ and tau aggregates. When we calculated the ratio 
of the radioactivity accumulation in the gray matter of the temporal lobe against the gray matter of the frontal 
lobe, the values varied with the kind of the substituted group introduced into the BIP scaffold (Table 1). All BIP 
derivatives showed higher radioactivity accumulation in the gray matter of the temporal lobe than that in the 
gray matter of the frontal lobe. In particular, the BIP derivatives (BIP-Me, BIP-OMe, and BIP-NMe2) with a 
compact substituted group showed a higher ratio than BIP-H which has no substituted group. Although BIP-Ph 
showed marked accumulation in the tau pathology, the selective binding of BIP-Ph in the τ pathology (3.3) was 
lower than that of BIP-Me (23.9), BIP-OMe (12.2), and BIP-NMe2 (12.9), because BIP-Ph also showed relatively 
high-level binding to Aβ plaques. Although IMPY also showed a ratio of 1.8, this value may reflect the ratio of 
Aβ aggregates deposited in the frontal and temporal lobes, and not tau aggregates. These findings in the in vitro 
autoradiographic studies revealed that the selective binding of BIP derivatives to tau aggregates can be markedly 
increased by introducing the compact substituted group into the BIP scaffold.
Brain uptake and clearance. Next, we evaluated uptake into and clearance from the brain after the injec-
tion of BIP derivatives into normal mice (Fig. 6 and Table 2). In order to obtain highly specific signals of tau 
aggregates, favorable tau imaging probes need to show not only high brain uptake early after administration but 
Figure 5. Quantitative analysis of in vitro autoradiography with AD brain sections. Data are presented as 
mean ± SEM (n = 3–7). Statistical significance was analyzed between temporal lobe and frontal groups in gray 








Table 1.  Ratio of radioactivity accumulation in the gray matter of the temporal lobe (a) against the gray 
matter of the frontal lobe (b).
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also rapid clearance from the brain because no tau aggregates exist in the brains of normal mice. We determined 
the log P-values of the 125I-labeled BIP derivatives, and the values ranged from 2.64 to 3.37. A previous report 
suggested that the low-molecular-weight compounds, which have moderate log P-values ranging from 1 to 3, suf-
ficiently penetrate the blood-brain barrier32. Since the BIP derivatives showed moderate lipophilicity close to the 
appropriate log P-values reported in the previous paper, they were expected to penetrate the blood-brain barrier. 
All BIP derivatives displayed high brain uptake, ranging from 3.5 to 4.7% ID/g, at 2 min postinjection. Thereafter, 
the radioactivity in the brain cleared with time, and it decreased to 0.12–0.65% ID/g at 30 min postinjection and 
0.04–0.23% ID/g at 60 min postinjection. When we calculated the ratio of the radioactivity accumulation of the 
BIP derivatives, the values ranged from 5 to 40 for 2 min/30 min and from 15 to 104 for 2 min/60 min, indicating 
that the BIP derivatives showed rapid clearance from the brain. Initial brain uptake of the BIP derivatives at 2 min 
postinjection were well correlated with their molecular weight, and not their log P-values. In other words, as the 
molecular weight of the BIP derivatives decreased, they showed higher brain uptakes. In particular, BIP-H and 
BIP-Me with log P-values with over 3 showed faster clearance from the brain than other BIP derivatives with log 
P-values less than 3. In addition, the BIP derivatives with a higher molecular weight tended to be cleared from the 
brain faster in comparison with the BIP derivatives with a lower molecular weight. Previous studies reported that 
the maximum brain uptake of [11C]PBB322, [18F]THK-535118, and [18F]T80719, which are tau-PET imaging probes 
used in clinical research, showed 1.92, 4.35, and 4.43% ID/g at 1 or 2 min postinjection, respectively. Thereafter, 
the radioactivity accumulated in the brain cleared with time, and it was reduced to 0.11, 0.21, and 0.62% ID/g at 
30 min postinjection for [11C]PBB3, [18F]THK-5351, and [18F]T807, respectively. The ratio of the radioactivity 
accumulation at 1 or 2 min, and 30 min postinjection was 17.5, 20.7, and 7.15 for [11C]PBB3, [18F]THK-5351, and 
[18F]T807, respectively. A comparison of these values revealed that some of the radioiodinated BIP derivatives 
have superior radioactivity pharmacokinetics in the brain. The findings suggest that the BIP derivatives may be 
applicable to clinical use from the viewpoint of radioactivity pharmacokinetics in the brain, in addition to highly 
selective binding to tau aggregates. The biodistribution of BIP derivatives in the whole mouse body displayed 
typical pharmacokinetics of lipophilic compounds, which means high uptake into the liver and the subsequent 
excretion into the intestine (Table S1). In addition, the low accumulation of BIP derivatives in the thyroid also 
demonstrated high stability against deiodination in vivo.
When we determined the stability of [125I]BIP-NMe2 in the blood by HPLC analyses, the HPLC profile after 
incubation for 60 min was similar to that of the intact form, suggesting that they showed high stability in the 
blood (Figure S3). Furthermore, we analyzed the radiometabolites in the blood and brain after the injection 
of [125I]BIP-NMe2 into normal mice. When the radioactivity level was analyzed in plasma by HPLC after the 
injection of [125I]BIP-NMe2 into normal mice, we found that [125I]BIP-NMe2 converted to some radiometabolites 
with different chemical forms (Fig. 7A). The percent of the intact form decreased with time and reached 63.6 and 
16.8% at 2 and 10 min after the injection, respectively. This result regarding in vivo metabolism in the blood was 
Figure 6. Comparison of uptake into and clearance from the brain after intravenous injection of 
125I-labeled BIP derivatives into normal mice (n = 5). 
Compound
% ID/g in brain Ratio
Molecular weight log P2 min 30 min 60 min 2 min/30 min 2 min/60 min
[125I]BIP-Ph 3.51 ± 0.20 0.65 ± 0.06 0.23 ± 0.03 5.4 15.3 370 2.64 ± 0.03
[125I]BIP-H 4.74 ± 0.57 0.12 ± 0.01 0.06 ± 0.01 39.5 79.0 294 3.22 ± 0.04
[125I]BIP-Me 4.28 ± 0.50 0.14 ± 0.03 0.04 ± 0.00 30.6 107.0 308 3.37 ± 0.02
[125I]BIP-OMe 4.30 ± 0.41 0.17 ± 0.02 0.08 ± 0.03 25.3 53.8 324 2.71 ± 0.01
[125I]BIP-NMe2 3.98 ± 0.32 0.38 ± 0.03 0.16 ± 0.01 10.5 24.9 337 2.40 ± 0.05
Table 2.  Brain uptake of 125I-labeled BIP derivatives after intravenous injection into normal micea, 
molecular weight, and log P-valueb of 125I-labeled BIP derivatives. aEach value represents the mean ± SD of 
five animals. bEach value represents the mean ± SD of three experiments.
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comparable to that of [18F]THK-5351 reported in a previous paper33, suggesting that [125I]BIP-NMe2 has in vivo 
stability sufficient for clinical trials. The difference in the stability of [125I]BIP-NMe2 between in vitro and in vivo 
may be involved in the different characteristics of radiometabolites formed by the in vivo metabolism of [125I]
BIP-NMe2 in organs including the liver and kidney. When we analyzed the radioactivity in the brain by HPLC at 
2 and 10 min postinjection of [125I]BIP-NMe2, 84.7 and 62.0% of [125I]BIP-NMe2 at 2 and 10 min postinjection, 
respectively, existed in the brain as an intact form (Fig. 7B), indicating that [125I]BIP-NMe2 may be sufficiently 
applicable for the in vivo imaging of tau aggregates. It is generally accepted that the in vivo metabolism of radi-
otracers is different between mice and human subjects. Therefore, further investigation of the characteristics of 
radiometabolies derived from BIP derivatives in human subjects is essential for clinical application.
Conclusions
In the present study, we newly designed and synthesized radioiodinated BIP derivatives with various substituted 
groups, and evaluated their utility as tau-SPECT imaging probes. In in vitro autoradiographic studies using AD 
brain sections, the BIP derivatives depicted tau clearly. In addition, the in vitro autoradiographic studies also 
revealed highly selective binding of the BIP derivatives to the tau pathology compared with Aβ pathology. In 
the biodistribution study in normal mice, all BIP derivatives showed high uptake into and fast clearance from 
the brain comparable to the tau-PET imaging probes in clinical use. The results of the present study suggest that 
123I-labeled BIP derivatives with highly selective affinity for tau aggregates may be new candidates for in vivo 
detection of the tau pathology.
Materials and Methods
General remarks. All reagents were commercial products and used without further purification unless indi-
cated otherwise. All compounds were purified by Smart Flash EPCLC W-Prep 2XY (Yamazen corporation) unless 
indicated otherwise. 1H NMR spectra were recorded on a JNM-ECS400 (JEOL) with tetramethyl silane (TMS) as 
an internal standard. Coupling constants are reported in Hertz. Multiplicity was defined as singlet (s), doublet (d), 
or multiplet (m). ESI mass spectrometry was conducted with a SHIMADZU LCMS-2020. High-resolution mass 
spectrometry (HRMS) was carried out with a GCMate II (JEOL). HPLC was performed with a Shimadzu system 
Figure 7. HPLC analysis of radioactivity in the blood (A) and brain (B) after injection of [125I]BIP-NMe2 into 
mice (n = 4).
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(an LC-20AT pump with an SPD-20A UV detector, λ = 254 nm) using a Cosmosil C18 column (Nacalai Tesque, 
COSMOSIL 5C18-AR-II 4.6 mm I.D. × 150 mm) and acetonitrile/H2O (with or without TFA) as the mobile phase at 
a flow rate of 1.0 mL/min. All key compounds were proven by this method to show > 95% purity.
Animals. Animal experiments were conducted in accordance with our institutional guidelines and were 
approved by the Kyoto University Animal Care Committee. Male ddY mice were purchased from Japan SLC, 
Inc. (Shizuoka, Japan), and were fed standard chow and had free access to water. We made all efforts to minimize 
suffering.
Human brain tissues. Experiments involving human subjects were performed in accordance with relevant 
guidelines and regulations and were approved by the ethics committee of Kyoto University. Informed consent was 
secured from all subjects in this study. Postmortem brain tissues from an autopsy-confirmed case of AD (male, 76 
years old) were obtained from the Graduate School of Medicine, Kyoto University.
Chemistry. Compounds 1 and 5 were synthesized according to a method reported previously27,28. We used 
compounds 2, 3, and 4 of commercially available products.
7-Bromo-3-phenylpyrido[1,2-a]benzimidazole (6). A mixture of 127 (645 mg, 2.75 mmol), 
2,4-dibromopyridine (690 mg, 2.75 mmol) and CuI (105 mg, 0.550 mmol), Cs2CO3 (2.67 g, 8.26 mmol), and 
1,10-phenanthroline (198 mg, 1.10 mmol) in xylene (30.0 mL) was stirred under reflux for 24 h. The mixture 
was extracted with ethyl acetate (100 mL), and the organic phase was separated and dried over MgSO4. The sol-
vent was removed and the residue was purified by silica gel chromatography (ethyl acetate/hexane = 1/2) to give 
78.4 mg of 6 (8.80%). 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 7.2 Hz, 1H), 8.08 (s, 1H), 7.88 (s, 1H), 7.77 (d, 
J = 8.7 Hz, 1H), 7.72 (d, J = 7.2 Hz, 2H), 7.45–7.55 (m, 4H), 7.19 (d, J = 7.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) 
δ 146.4, 142.9, 141.4, 138.1, 129.2, 129.1, 127.0, 125.0, 124.1, 122.5, 119.0, 114.4, 111.5, 111.01, 110.97. MS (ESI) 
m/z 323.1 [MH+].
7-Bromopyrido[1,2-a]benzimidazole (7). The same reaction described above to prepare 6 was used, and 
834 mg of 7 was obtained in a yield of 67.8%. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 6.7 Hz, 1H), 8.31 (d, 
J = 8.4 Hz, 1H), 8.01 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 9.3 Hz, 1H), 7.60–7.64 (m, 1H), 7.52 (dd, J = 8.7, 1.7 Hz, 1H), 
7.06 (dd, J = 6.7, 6.7 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 149.1, 145.6, 129.9, 127.5, 125.1, 124.0, 122.5, 118.9, 
118.0, 111.5, 110.8. MS (ESI) m/z 247.1 [MH+].
7-Bromo-3-methylpyrido[1,2-a]benzimidazole (8). The same reaction described above to prepare 6 
was used, and 62.4 mg of 8 was obtained in a yield of 23.9%. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 7.0 Hz, 
1H), 8.02 (s, 1H), 7.70 (d, J = 8.7 Hz, 1H), 7.40–7.43 (m, 2H), 6.72 (d, J = 7.0 Hz, 1H), 2.48 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 149.6, 145.8, 141.5, 127.5, 124.1, 123. 3, 122.1, 118.5, 115.9, 113.5, 111.2, 21.9. MS (ESI) m/z 
261.1 [MH+].
7-Bromo-3-methoxypyrido[1,2-a]benzimidazole (9). The same reaction described above to prepare 
6 was used, and 223 mg of 9 was obtained in a yield of 8.05%. 1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 7.5 Hz, 
1H), 7.95 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 8.7 Hz, 1H), 7.38 (dd, J = 8.4, 1.7 Hz, 1H), 6.87 (d, J = 2.3 Hz, 1H), 6.59 
(dd, J = 7.5, 2.6 Hz, 1H), 3.93 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 161.5, 151. 4, 146.4, 127.6, 125.4, 123.1, 121.6, 
118.1, 110.7, 106.5, 93.9, 55.7. MS (ESI) m/z 277.1 [MH+].
7-Bromo-3-dimethylaminopyrido[1,2-a]benzimidazole (10). 2-Bromo-N,N-dimethylpyridin-
4-amine (5) was synthesized according to the method reported previously28. Using 5, the same reaction described 
above to prepare 6 was used, and 94.9 mg of 10 was obtained in a yield of 6.00%. 1H NMR (400 MHz, CDCl3) 
δ 8.16 (d, J = 7.5 Hz, 1H), 7.86 (s, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 7.5 Hz, 1H), 
6.55 (s, 1H), 3.14 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 152.5, 150.8, 147.0, 127.7, 124.8, 121.5, 120.5, 117.8, 
110.1, 102.3, 90.8, 40.0. MS (ESI) m/z 290.1 [MH+].
7-Tributylstannyl-3-phenylpyrido[1,2-a]benzimidazole (11). A mixture of 6 (95.0 mg, 0.294 mmol), 
bis(tributyltin) (295 μ L, 0.588 mmol), and (Ph3P)4Pd (146 mg, 0.126 mmol) in a mixed solvent (36.0 mL, dioxane/
Et3N = 2/1) was stirred under reflux for 3 h. The solvent was removed, and the residue was purified by silica gel 
chromatography (ethyl acetate/hexane = 1/2) to give 26.7 mg of 11 (17.0%). 1H NMR (400 MHz, CDCl3) δ 8.48 
(d, J = 7.3 Hz, 1H), 8.08 (s, 1H), 7.87–7.89 (m, 2H), 7.72 (d, J = 7.5 Hz, 2H), 7.44–7.53 (m, 4H), 7.12 (dd, J = 7.2, 
1.7 Hz, 1H), 0.87–1.63 (m, 27H). 13C NMR (100 MHz, CDCl3) δ 148.5, 145.1, 142.0, 139.0, 138.4, 129.1, 128.8, 
128.6, 128.3, 127.8, 126.9, 125.0, 114.4, 110.1, 110.0, 29.1, 27.4, 13.7, 9.8. MS (ESI) m/z 535.4 [MH+].
7-Tributylstannylpyrido[1,2-a]benzimidazole (12). The same reaction described above to prepare 11 
was used, and 510 mg of 12 was obtained in a yield of 32.8%. 1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 7.0 Hz, 
1H), 8.08 (s, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 9.3 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.40–7.42 (m, 1H), 
6.84 (dd, J = 7.0, 7.0 Hz, 1H), 0.87–1.64 (m, 27H). 13C NMR (100 MHz, CDCl3) δ 147.9, 144.4, 138.8, 129.1, 128.6, 
128.2, 127.9, 125.0, 117.9, 110.0, 109.8, 29.0, 27.3, 13.6, 9.8. MS (ESI) m/z 459.3 [MH+].
7-Tributylstannyl-3-methylpyrido[1,2-a]benzimidazole (13). The same reaction described 
above to prepare 11 was used, and 14.9 mg of 13 was obtained in a yield of 13.2%. 1H NMR (400 MHz, CDCl3) 
δ 8.31 (d, J = 7.0 Hz, 1H), 8.02 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.38–7.42 (m, 2H), 6.66 (d, J = 7.0 Hz, 1H), 2.46 
(s, 3H), 1.53–1.61 (m, 6H), 1.32–1.39 (m, 6H), 1.10–1.14 (m, 6H), 0.86–0.91 (m, 9H). 13C NMR (100 MHz, CDCl3) 
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δ 148.6, 144.7, 140.5, 138.4, 128.7, 127.8, 127.6, 124.2, 116.0, 112.9, 109.6, 29.1, 27.4, 21.9, 13.7, 9.8. MS (ESI) m/z 
473.3 [MH+].
7-Tributylstannyl-3-methoxypyrido[1,2-a]benzimidazole (14). The same reaction described above 
to prepare 11 was used, and 47.9 mg of 14 was obtained in a yield of 23.9%. 1H NMR (400 MHz, CDCl3) δ 8.24 
(d, J = 7.5 Hz, 1H), 7.95 (s, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 6.54 (dd, 
J = 7.2, 2.3 Hz, 1H), 3.93(s, 3H), 1.54–1.60 (m, 6H), 1.32–1.37 (m, 6H), 1.09–1.13 (m, 6H), 0.87–0.90 (m, 9H). 13C 
NMR (100 MHz, CDCl3) δ 161.0, 150.1, 145.1, 137.8, 128.7, 127.5, 126.9, 125.4, 109.2, 105.8, 93.9, 55.6, 29.1, 27.4, 
13.7, 9.7. MS (ESI) m/z 489.3 [MH+].
7-Tributylstannyl-3-dimethylaminopyrido[1,2-a]benzimidazole (15). The same reaction described 
above to prepare 11 was used, and 18.0 mg of 15 was obtained in a yield of 11.0%. 1H NMR (400 MHz, CD3OD) δ 
8.41 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.66 (s, 1H), 7.24 (d, J = 7.5 Hz, 1H), 6.65 (dd, J = 7.8, 2.6 Hz, 1H), 
6.32 (d, J = 2.3 Hz, 1H), 3.06 (s, 6H), 1.56–1.63 (m, 6H), 1.32–1.41 (m, 6H), 1.10–1.14 (m, 6H), 0.88–0.92 (m, 9H). 
13C NMR (100 MHz, CDCl3) δ 151.2, 150.6, 137.3, 128.7, 126.3, 126.0, 124.8, 108.7, 101.9, 99.9, 91.2, 40.1, 29.1, 
27.4, 13.7, 9.8. MS (ESI) m/z 502.4 [MH+].
7-Iodo-3-phenylpyrido[1,2-a]benzimidazole (16, BIP-Ph). To a solution of 11 (24.7 mg, 
0.0463 mmol) in chloroform (15.0 mL) was added a solution of iodine in chloroform (1.00 mL, 50 mg/mL) at 
room temperature. The mixture was stirred for 1.5 h, and saturated NaHSO3 aq. was added to quench the reac-
tion. The mixture was extracted with chloroform (100 mL), and the organic phase was separated and dried over 
MgSO4. The solvent was removed and the residue was purified by silica gel chromatography (ethyl acetate/hex-
ane = 1/2) to give 16 (10.3 mg, 60.2%). 1H NMR (400 MHz, DMSO-d6) δ 9.18 (d, J = 7.3 Hz, 1H), 8.19–8.22 (m, 
2H), 7.93–7.99 (m, 3H), 7.66 (dd, J = 8.4, 1.4 Hz, 1H), 7.51–7.57 (m, 2H), 7.46–7.51 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 149.1, 146.2, 143.2, 137.9, 129.7, 129.2, 129.1, 128.6, 127.9, 127.0, 125.0, 114.2, 111.9, 111.2, 90.0. HRMS 
(EI) m/z calcd. for C17H11IN2 (M+) 369.9967, found 369.9960.
7-Iodopyrido[1,2-a]benzimidazole (17, BIP-H). The same reaction described above to prepare 16 was 
used, and 210 mg of 17 was obtained in a yield of 64.2%. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, J = 6.7, 
0.9 Hz, 1H), 8.17–8.19 (m, 2H), 7.59–7.70 (m, 3H), 7.05 (dd, J = 6.7, 6.7 Hz, 1H). 13C NMR (100 MHz, CDCl3) 
δ 148.8, 146.1, 129.9, 129.5, 128.9, 128.1, 125.1, 118.1, 111.8, 110.8, 89.7. HRMS (EI) m/z calcd. for C11H7IN2 (M+) 
293.9654, found 293.9660.
7-Iodo-3-methylpyrido[1,2-a]benzimidazole (18, BIP-Me). The same reaction described above to 
prepare 16 was used, and 5.50 mg of 18 was obtained in a yield of 65.2%. 1H NMR (400 MHz, CDCl3) δ 8.29 (d, 
J = 7.0 Hz, 1H), 8.24 (d, J = 1.2 Hz, 1H), 7.60 (s, 2H), 7.43 (s, 1H), 6.72 (d, J = 7.2 Hz, 1H), 2.48 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 149.2, 146.2, 141.5, 128.8, 128.4, 128.0, 124.1, 115.9, 113.5, 111.6, 89.3, 21.9. HRMS (EI) m/z 
calcd. for C12H9IN2 (M+) 307.9811, found 307.9808.
7-Iodo-3-methoxypyrido[1,2-a]benzimidazole (19, BIP-OMe). The same reaction described above 
to prepare 16 was used, and 14.2 mg of 19 was obtained in a yield of 56.3%. 1H NMR (400 MHz, CDCl3) δ 8.20 (d, 
J = 7.5 Hz, 1H), 8.17 (d, J = 1.2 Hz, 1H), 7.51–7.57 (m, 2H), 6.86 (d, J = 2.3 Hz, 1H), 6.56 (dd, J = 7.5, 2.3 Hz, 1H), 
3.93 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 161.7, 151.0, 146.5, 128.8, 128.2, 127.8, 125.5, 111.2, 106.8, 94.0, 89.0, 
55.8. HRMS (EI) m/z calcd. for C12H9IN2O (M+) 323.9760, found 323.9762.
7-Iodo-3-dimethylaminopyrido[1,2-a]benzimidazole (20, BIP-NMe2). The same reaction 
described above to prepare 16 was used, and 5.50 mg of 20 was obtained in a yield of 16.7%. 1H NMR (400 MHz, 
CD3OD) δ 8.75 (d, J = 7.8 Hz, 1H), 7.94 (s, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 7.8 Hz, 
1H), 6.56 (s, 1H), 3.25 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 152.1, 150.1, 147.5, 128.3, 127.1, 126.7, 124.8, 110.6, 
102.4, 90.7, 88.6, 40.1. HRMS (EI) m/z calcd. for C13H12IN3 (M+) 337.0076, found 337.0074.
Radiolabeling. The radioiodinated forms of ligands were prepared from the corresponding tributyltin pre-
cursors by iododestannylation. Briefly, to initiate the reaction, a tributyltin precursor (200 μ g/200 μ L EtOH) was 
added to a mixture of [125I]NaI (3.70–7.40 MBq, specific activity: 81.4 TBq/mmol) in 20 μ L EtOH, 100 μ L of 3% 
H2O2 aq., and 100 μ L of 1 N HCl aq. in a sealed vial. The reaction to obtain radioiodinated ligands was allowed to 
proceed at room temperature for 40 min and terminated by the addition of saturated NaHSO3 aq. (200 μ L). After 
neutralization with sodium hydrogen carbonate and extraction with ethyl acetate, the organic phase was dried 
by passing through a column filled with anhydrous Na2SO4. The solution was gas-dried with a stream of nitrogen 
gas. The crude radioiodinated ligands were purified by HPLC on a COSMOSIL 5C18-AR-II column with an iso-
cratic solvent of acetonitrile/H2O (with or without TFA) at a flow rate of 1.0 mL/min.
Measurement of log P values. The partition coefficients of each radioiodinated ligand were determined 
according to the conventional method25.
In vitro autoradiography. The presence and location of tau and Aβ deposits in the AD brain sections were 
confirmed with immunohistochemical staining using an anti-phosphorylated tau antibody (AT8) and Aβ 1–42 
antibody (BC05), respectively (See the Supporting Information). [125I]IMPY was synthesized according to the 
method reported previously32. Six-micrometer-thick serial sections of paraffin-embedded blocks were used for 
staining. The sections were subjected to two 15-min incubations in xylene, two 1-min incubations in 100% EtOH, 
one 1-min incubation in 90% EtOH, and one 1-min incubation in 70% EtOH to completely deparaffinize them, 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:34197 | DOI: 10.1038/srep34197
followed by two 2.5-min washes in water. The sections were incubated with radioiodinated ligands (370 kBq/mL 
in 10% or 50% EtOH) for 2 h at room temperature. They were then dipped in 50% EtOH for 1 h and washed with 
H2O for 1 min. After drying, the 125I-labeled sections were exposed to a BAS imaging plate (Fuji Film) overnight. 
Autoradiographic images were obtained using a BAS5000 scanner system (Fuji Film). A two-tailed, unpaired 
t-test, with Welch’s correction as necessary, was performed to determine the significance of the difference in 
radioactivity accumulation in the gray matter between the frontal and temporal lobes. Statistical analyses were 
performed with GraphPad Prism 5 (GraphPad Software, Inc.).
In vitro blocking study. We used the same postmortem brain tissues as employed for in vitro autoradiogra-
phy. The sections were incubated with [125I]BIP-NMe2 (370 kBq/mL in 10% EtOH) for 2 h at room temperature in 
the presence or absence of nonradioactive BIP-NMe2 (1 or 10 μ M). After incubation, we dipped the sections and 
exposed them to a BAS imaging plate with the same methods as in vitro autoradiographic studies. The autoradio-
graphic images were obtained using a BAS5000 scanner system.
Brain uptake and clearance in normal mice. A saline solution (100 μ L) of each [125I]BIP derivative 
(19.6-29.4 kBq) containing ethanol (10.0 μ L) and Tween 80 (0.100 μ L) was injected intravenously directly into the 
tails of ddY mice (5 weeks old, male). The mice were sacrificed at various time-points postinjection. The brains 
were removed and weighed, and the radioactivity was measured with an automatic γ counter (Wallac WIZARD 
1470, PerkinElmer).
Analysis of radiometabolites in blood and brain. We performed the HPLC analyses of radiometab-
olites in the blood and brain according to a previously reported method26. [125I]BIP-NMe2 (1.11–1.48 MBq in 
150 μ L) was injected into the tail vein of ddY mice (n = 4 for each time point for the blood and brain). The mice 
were sacrificed at 2 and 10 min postinjection. Bood samples were obtained and centrifuged at 4,000 × g for 5 min 
at 4 °C. The plasma (200 μ L) was separated and transferred to a tube containing acetonitrile (200 μ L). The mix-
ture was stirred in precipitate from the aqueous phase. The brain was removed from the mice at 2 and 10 min 
postinjection of [125I]BIP-NMe2, and homogenized in test tubes containing 500 μ L of tris-buffered saline with 
a homogenizer (POLYTRON PT 10–35, KINEMATICA). Acetonitrile (500 μ L) was added to a tube containing 
homogenized brain tissue and centrifuged at 4,000 × g for 5 min at 4 °C. The supernatants of the plasma and brain 
homogenates were filtrated using a 0.45-μ m filter (Millipore). Then, the filtrate was analyzed using HPLC on a 
COSMOSIL 5C18-AR-II column with an isocratic solvent of acetonitrile/H2O/TFA (25/75/0.1) at a flow rate of 
1.0 mL/min. The eluent was collected with a fraction collector (Frac-920, GE Healthcare) at 30-s intervals, and 
the radioactivity in each fraction (500 μ L) was measured with an automatic γ counter (Wallac WIZARD 1470).
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